A tale of two receptors:Insulin and insulin-like growth factor signaling in cancer

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. See related articles by Jones et al., p. 693, and Puzanov et al., p. 701

Original languageEnglish (US)
Pages (from-to)667-669
Number of pages3
JournalClinical Cancer Research
Volume21
Issue number4
DOIs
StatePublished - Feb 15 2015

Fingerprint Dive into the research topics of 'A tale of two receptors:Insulin and insulin-like growth factor signaling in cancer'. Together they form a unique fingerprint.

Cite this